Background. Xpert MTB/RIF (Xpert) detects rifampicin-resistant tuberculosis (RR-tuberculosis), enabling physicians to rapidly initiate a World Health Organization-recommended 5-drug regimen while awaiting second-line drug-susceptibility test (DST) results. We quantified the second-line DST results time and proportion of patients potentially placed on suboptimal therapy.
that a second sample be evaluated by the MTBDRplus line probe assay (LPA; Hain Lifescience GmbH, Nehren, Germany) to confirm MDR tuberculosis (testing for isoniazid [INH] and confirming RIF) and by culture-based DST to determine resistance to second-line injectable drugs (amikacin [AMI] or kanamycin [KAN] ) and fluoroquinolones (ofloxacin [OFX] ) [8] . The national guidelines instruct that patients start the standardized MDR tuberculosis regimen within 5 days of the Xpert result [8, 9] . In line with the WHO guidelines, the standardized regimen consists of 5 drugs: KAN, moxifloxacin (MOXI), ethionamide (ETH), pyrazinamide (PZA), and terizidone.
Our aim in this study was to determine the proportion of patients evaluated using second-line DST (culture for AMI or KAN plus OFX susceptibility), the time until availability of second-line DST results, the variables associated with lack and/or delay of second-line DST results, and the proportion of RIFresistant tuberculosis patients potentially placed on empiric suboptimal therapy, defined as fewer than 4 likely effective drugs.
METHODS

Patient Population
Western Cape Province
A retrospective observational study included all patients diagnosed with RIF-resistant tuberculosis by Xpert performed at the National Health Laboratory Services (NHLS), Cape Town, South Africa, from November 2011 to June 2013. With the exception of a few hospitals and clinics, all samples from Western Cape patients with presumed tuberculosis are sent to NHLS. According to the Western Cape DOH tuberculosis guidelines, 2 sputum specimens are sent to the NHLS: 1 for Xpert and 1 for LPA and culture-based DST if Xpert indicates RIF resistance. The request for 2 samples at screening is unique to this province and thus an interesting comparator for the other provinces.
Using the NHLS database, we identified all patients with RIF-resistant Mycobacterium tuberculosis on Xpert and linked patients' first and second sputum specimens by matching name, age, sex, and location. We abstracted acid-fast bacilli (AFB) sputum grade, RIF and INH LPA resistance results, and culture-based second-line DST results and result date. The Stellenbosch University's Health Research Ethics Committee and the Boston University Medical Center Institutional Review Board (IRB) approved the study.
Eastern Cape, Free State, and Gauteng Province
A prospective observational study included a sample of adults (aged ≥18 years) diagnosed with RIF-resistant MTB by Xpert between November 2012 and December 2013 in the NHLS of 3 South African provinces (Eastern Cape, Free State, and Gauteng). These provinces follow national DOH guidelines, which require collection of 1 sputum specimen at baseline for Xpert testing and a second subsequent sample for additional testing (LPA and culture-based DST) only if RIF-resistant tuberculosis is diagnosed on the first specimen.
We collected data on age, sex, AFB sputum grade, RIF and INH LPA resistance results, culture-based second-line DST results, and result date through review of the NHLS database and clinic files. The Stellenbosch University Health Research Ethics Committee and the University of North Carolina IRB approved the study.
Specimen Preparation and Drug-Susceptibility Testing
At NHLS, specimens are decontaminated in a standard method. An initial aliquot is used for auramine smear; a second aliquot for MTBDRplus LPA (version 2) [10] is used to assess the rpoB gene (RIF resistance) and the katG and inhA promoter genes (INH and ETH resistance) [11] ; and a third aliquot is used for BACTEC MGIT 960 system culture (BD Diagnostics Systems, Maryland). DST is performed on all positive cultures using the 1% proportion method on 7H11 agar slants that contain OFX (2 µg/mL), AMI (4 µg/mL), or KAN (6 µg/mL) [12] . Secondline injectable resistance is defined as AMI or KAN resistance, given their high levels of cross resistance [13] . OFX resistance is used as the indicator for MOXI, the fluoroquinolone used in the standard MDR tuberculosis regimen [14] .
Drug-resistant tuberculosis isolates have been collected from NHLS and deposited in our laboratory at Stellenbosch University since 2001. For this study, we found stored isolates from identified patients that were viable and performed PZA testing through amplification of the pncA gene, as previously described [15] . PZA testing is not performed at NHLS and is not routinely available. When results from the MTBDRplus assay were unavailable, targeted gene sequencing was also performed in our laboratory to confirm RIF resistance and determine resistance to INH and ETH. Terizidone DST is not performed due to its instability in culture [16] .
Statistical Analyses
Descriptive statistics were used to calculate the proportions of patients with second-line DST results available and distribution of drug-resistance profiles. We calculated the proportion of patients potentially on a suboptimal regimen as those with 3 or fewer effective drugs based on second-line DST, MTBDRplus, and PZA sequencing, divided by all of the patients with those results. The χ 2 test was used to examine the association between patient characteristics and having second-line DST results. To assess for changes over time in acquisition of second-line DST, we used visual inspection to look for linear trends and a generalized additive model with logit link to look for nonlinear trends in Western Cape Province and separately in the other provinces. Logistic regression was used to study potential correlates with second-line DST. Turnaround time for second-line DST results was calculated by subtracting the date of specimen collection and/or Xpert test request from the date of NHLS DST result reporting. The χ 2 test was used to compare the probability of second-line DST results by availability of pncA results. A negative binomial regression model was used to assess turnaround time by smear status, provincial group, sex, and age (dichotomized as ≤10 years and >10 years). Analyses were conducted using Matlab, version R2012B, and SAS, version 9.3. All statistical tests were 2-sided and significance was determined at P = .05.
RESULTS
Characteristics of the Study Population
Among 1332 Of the 596 patients diagnosed with RIF-resistant tuberculosis on Xpert with available second-line DST results, mean age was 34.1 years (standard deviation, 11.5), 245 (41.1%) were female, and 332 (58.3%) were smear positive (Table 1) . Of the 585 (98.2%) patients with LPA or targeted sequencing results, 468 (80.0%) had INH-resistance mutations and 574 (98.6%) had RIF-resistance mutations detected. Patients from the Western Cape were younger (P = .0001), due to inclusion of children in that province, and had more INH resistance detected (P = .003) than patients from the other provinces (Table 1) .
Using a generalized additive model, we found in the Western Cape the odds of getting a second-line test decreased by 3% every 30 days (P = .03) and was 0.56 (95% CI, 0.53-0.59). The probability of a second-line test in the other provinces did not significantly change over time (P = .70) and was estimated to be 0.26 (95% CI, 0.22-0.30). In Western Cape, children (aged ≤10 years; n = 32) were 51% less likely to have second-line DST than patients aged >10 years (RR = 0.49; 95% CI, 0.26-0.79). Patients with smear-negative disease were less likely to have second-line DST results than patients with smear-positive disease (RR = 0.72; 95% CI, 0.64-0.81). Gender was not associated with likelihood of having a second-line DST result (RR = 1.1; 95% CI, 0.97-1.24) and did not significantly change after controlling for province.
Second-Line DST Turnaround Time and Results
Median turnaround time for second-line DST was 53 days (range, Among the 549 patients with DST results for AMI/KAN, OFX, and ETH, 326 (59.4%) had resistance to 1 or more second-line drugs, including 71 (12.9%) with preextensively drug-resistant (pre-XDR) tuberculosis and 38 (6.9%) with XDR tuberculosis (Table 2 ). These proportions were similar for the Western Cape and other provinces, except that patients from the Western Cape were more likely to have any additional resistance (RR = 1.92; 95% CI, 1.45-2.57) due to more ETH resistance (RR = 4.06; 95% CI, 2.31-7.17; Table 2 ). Among these 549 patients, 252 (45.9%) had pncA results, of which 137 (54.4%) were PZA resistant based on any mutation in the pncA gene and promoter region. Characteristics of patients with and without pncA data were similar except that Western Cape patients without pncA results were more likely to have ETH resistance (RR = 1.41; 95% CI, 1.13-1.77) than Western Cape patients with pncA results (Table 2 ).
In the 252 patients with DST data on AMI/KAN, OFX, ETH, and PZA, the standard MDR tuberculosis regimen (KAN, MOXI, ETH, PZA, and terizidone) would only provide 5 effective drugs to 31.4% and 4 effective drugs to 28.6% of patients (if terizidone is assumed effective in all; Table 3 ). The percentage of patients with likely effective drugs if started on the standard regimen is depicted in Figure 2 . Following the South African DOH guidelines, an ineffective regimen would be initiated empirically in 40.1% of these patients, with 7.9% receiving only 1, 8.3% receiving 2, and 23.8% receiving 3 effective drugs. The standard MDR tuberculosis regimen was more likely to contain only 3 effective drugs (RR = 2.96; 95% CI, 1.48-5.95) or to be a suboptimal baseline regimen (RR = 1.84; 95% CI, 1.23-2.79) for patients from Western Cape than patients from the other provinces (Table 3) . e More patients from Western Cape had any additional resistance than patients from the other provinces (P < .0001). [17] [18] [19] . The severity of the problem differed by region. Compared to patients in the other provinces, Western Cape patients were twice as likely to have second-line DST results (44.7% vs 26.2%) but almost half as likely to initiate an effective MDR-tuberculosis treatment regimen (46.8% vs 25.3%). We found a slight decreasing trend in likelihood of having a second-line DST in the Western Cape, reflecting the challenge of maintaining this algorithm. The higher prevalence of available DST results in the Western Cape likely reflects the unique provincial guidelines that recommend collection of 2 baseline samples. The lower effectiveness of the standard MDR-tuberculosis regimen in the Western Cape was due to the higher prevalence of ETH resistance.
The finding that many patients, especially those with smear-negative disease and children, failed to have second-line DST results reflects the technical challenge of getting good-quality specimens for culture-based tests [20, 21] . Our data confirm prior studies that showed that operational challenges in getting a second sample contribute to difficulty in constructing an effective treatment regimen [22] and support guidelines that recommend the collection of 2 samples at baseline in all people with presumptive tuberculosis so that the first specimen can be dedicated to Xpert testing and a second to LPA and/or phenotypic DST [23] . This recommendation of 2 baseline specimens should be extended to all countries where the tuberculosis diagnostic algorithm mirrors that in South Africa.
Few studies have reported second-line DST results to the same level of granularity or explored the time element that we present. Our findings are in line with those published by the Preserving Effective TB Treatment Study (PETTS), conducted in 9 countries between 2005 and 2008. The PETTS group found that 43.7% of MDR-tuberculosis patients had resistance to at least 1 second-line drug, ranging from 33.3% in Thailand to 62% in Latvia [24] . In South Africa, 44.7% of MDR-tuberculosis patients had resistance to at least 1 second-line drug, but this cohort excluded patients previously treated for MDR tuberculosis and did not perform PZA DST; half of MDR tuberculosis specimens are resistant to PZA globally, so their South Africa resistance estimate is likely a lower boundary [25] . The NHLS recently released the South African Tuberculosis Drug Resistance Survey, 2012-2014 [26] . They report frequent second-line drug resistance among MDR cases across South Africa, including 44.7% (95% CI, 25.9%-63.6%) ETH resistance, 59.1% (95% CI, 49%-69.1%) PZA resistance, and 13% (95% CI, 5%-21%) for both second-line injectables and OFX, which is similar to what we report in our cohort. Additionally, they report 4.9% (95% CI, 1%-8.8%) XDR tuberculosis, which is similar to our finding of 6.9% XDR tuberculosis.
The WHO recently endorsed the use of new drugs (bedaquiline and delamanid) and a novel, shortened 7-drug MDR tuberculosis regimen [27] . A caveat of this recommendation is that patients with known or highly suspected baseline resistance to any of the 7 drugs (except INH), including KAN, MOXI, ETH, and PZA, should not be started on the shortened regimen. Nearly half of our cohort would have resistance to at least 1 drug. The high frequency of resistance raises the question of this shorter regimen's effectiveness in South African patients. Ideally, standardized regimens should be built on local epidemiologic evidence regarding baseline resistance patterns in communities and contain new drugs with less risk of baseline resistance. Currently, information on ETH resistance can be obtained by inhA promoter mutation presence on the MTBDRplus LPA assay [11] . Resistance to fluoroquinolones and second-line injectables can also be obtained more rapidly using the MTBDRsl LPA (Hain Lifescience GmbH, Nehren, Germany), which was recently endorsed by the WHO [28] . Changes in the South African algorithm to implement the MTBDRsl would overcome many of the technical challenges our study revealed, including shortening turnaround time and reducing reliance on culture viability. As new drugs such as bedaquiline, delamanid, and linezolid become available [29] , careful monitoring for resistance will also need to occur.
While our study has many strengths, including the relatively large sample size and inclusion of a representative sample of 4 South African provinces, we do note limitations. First, the proportion of patients with second-line DST results may have been underestimated in the Western Cape as linkage of first and second specimens was done through a matching algorithm. Second, classification of ETH resistance based on inhA promoter mutation information may underestimate the prevalence of ETH resistance, as other molecular mechanisms are known to cause ETH resistance [11] . Third, generalizability may be limited beyond South Africa, especially to regions with less mature MDR-tuberculosis epidemics and those that do not use rapid diagnostics to screen for RIF resistance. Fourth, dictated by data availability, the study periods between the provinces were nearly, but not perfectly, overlapping. However, no major policy changes other than Xpert implementation were made during these years. Last, because we did not have access to treatment registries, we use the phrase "potentially started ineffective treatment"; all patients who did start treatment would receive the stated empiric regimen. The successful South African implementation of Xpert to screen all tuberculosis suspects means that more MDR-tuberculosis patients are identified and started on therapy earlier [30] . Although a major achievement, the combination of high baseline resistance rates to drugs included in the South African standardized MDR-tuberculosis regimen, the failure to generate second-line DST information in more than half of all RIF-resistant tuberculosis patients, and the long turnaround time of second-line DST could fuel amplification of resistance and treatment failure and worsen the resistance epidemic [19] [20] [21] . The possible negative consequences of screening for resistance to a single drug (RIF) and use of a standard MDR-tuberculosis regimen highlight the need for implementation of available rapid diagnostics for resistance to a broader panel of drugs, as well as the need for individualized MDR-tuberculosis treatment based on comprehensive knowledge of drug-resistance patterns.
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